In an interview with Technology Networks, Dr. Daniel Reker discusses how machine learning is improving data-scarce areas of drug discovery.
From fine-tuning open source models to building agentic frameworks on top of them, the open source world is ripe with projects that support AI development.
News Medical on MSN
AI model accelerates antibody production and clone selection
As instigators of immunity, monoclonal antibodies are marvels of modern medicine, lab-made proteins that can treat cancers, ...
Forbes contributors publish independent expert analyses and insights. Dr. Lance B. Eliot is a world-renowned AI scientist and consultant. In today’s column, I examine the recently revealed feature ...
A new platform is set to make AI fine-tuning accessible to developers of all skill levels, making deep customization possible without coding expertise or sky-high infrastructure costs. Vertical AI’s ...
What if you could take a innovative language model like GPT-OSS and tailor it to your unique needs, all without needing a supercomputer or a PhD in machine learning? Fine-tuning large language models ...
Through his Google fellowship, Stoica seeks to apply model merging to create a cutting-edge vision encoder. A vision encoder converts image or video data into numerical representations that computers ...
A Microsoft and Amazon joint effort makes neural networks easier to program and use with the MXNet and Microsoft Cognitive Toolkit frameworks Deep learning systems have long been tough to work with, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results